Key result
Elevated copeptin immediately post-PCI is linked to ~60% greater MACE risk.
Why the study?
The prognostic value of serum copeptin levels immediately after successful PCI for clinical outcomes in patients with AMI remains uncertain.
Do serum copeptin levels immediately after successful PCI predict MACE in patients with acute myocardial infarction?
Cohort (n=149)
Do serum copeptin levels immediately after successful PCI predict MACE in patients with acute myocardial infarction?
Odds Ratio: 1.6
p-value: p=0.005
High serum copeptin levels measured immediately after successful PCI in AMI patients are associated with an increased risk of long-term MACE, suggesting its utility as a prognostic biomarker.
May aid post-PCI risk stratification; leaves open incremental value over existing models.
BACKGROUND: Serum copeptin has been demonstrated to be useful in early risk stratification and prognostication of patients with acute myocardial infarction (AMI). However, the prognostic value of copeptin after percutaneous coronary intervention (PCI) for clinical outcomes remains uncertain. We investigated the prognostic role of serum copeptin levels immediately after successful PCI as a prognostic marker for major adverse cardiac events (MACE; comprising death, repeat PCI, recurrent MI, or coronary artery bypass grafting) in patients with AMI. METHODS: A retrospective study was performed in 149 patients with AMI who successfully received PCI. Serum copeptin levels were analyzed in blood samples collected immediately after PCI. The association between copeptin levels and MACE during the follow-up period was evaluated. RESULTS: MACE occurred in 34 (22.8%) patients during a median follow-up of 30.1 months. MACE patients had higher copeptin levels than non-MACE patients did. Multiple logistic regression analysis showed that the increase in serum copeptin levels was associated with increased MACE incidence (odds ratio=1.6, P=0.005). CONCLUSIONS: A high level of serum copeptin measured immediately after PCI was associated with MACE in patients with AMI during long-term follow-up. Serum copeptin levels can serve as a prognostic marker in patients with AMI after successful PCI.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2018) conducted a cohort in Acute myocardial infarction (n=149). Serum copeptin levels was evaluated on Major adverse cardiac events (MACE; comprising death, repeat PCI, recurrent MI, or coronary artery bypass grafting) (OR 1.6, p=0.005). Increased serum copeptin levels measured immediately after successful PCI were associated with a higher incidence of major adverse cardiac events (OR 1.6, P=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: